Morgan Stanley: Sino Biopharmaceutical licenses six early-stage oncology assets; upfront payment to be recognized mainly in 2027

How much revenue from the $7 billion deal can be recognized in the near term?

Sino Biopharmaceutical licensed six preclinical oncology assets to Boehringer Ingelheim in a deal valued at $7 billion, including $358 million in upfront payments. The company expects most of the upfront payment to be recognized in 2027, with the remainder potentially recognized in the first quarter of 2028.
Morgan Stanley considers the deal terms reasonable, given the programs’ preclinical stage, the separate payment of the option exercise fee, and customary milestone and sales-royalty terms.

The assets are mainly antibody-drug conjugates (ADCs), including bispecific and dual-payload ADCs, as well as T-cell engagers (TCEs) developed using LaNova’s tumor microenvironment platform. Five of the six assets come from the company’s wholly owned LaNova platform, and one comes from Beijing Tide.
The company is responsible for development through completion of global Phase I trials, after which Boehringer Ingelheim will exercise its option. The company expects the first program to enter clinical trials in 2027 and potentially complete Phase I by the end of 2028.

The $200 million upfront payment related to the AstraZeneca deal was received in October 2026 and recognized in that year; by contrast, the upfront payment from the Boehringer Ingelheim deal will be reflected mainly in 2027.
Merck expects MK-2010 to enter global Phase III trials in 2027, which will trigger an additional milestone payment to the company. Management is also optimistic about the globalization and business development potential of other pipeline assets.
The company reaffirmed its full-year 2026 guidance for a selling, general and administrative expense ratio of 35%. Morgan Stanley estimates underlying profit of RMB 5.3 billion for the same period, and rates the stock Overweight with a target price of HK$8.60.